Search clinical trials for: Cadonilimab regorafenib

Total 385 results

Shanghai Zhongshan Hospital
Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Hepatocellular Carcinoma

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Gastric Cancer | Esophagogastric Junction Cancer

China
Universitair Ziekenhuis Brussel

Recruiting

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma (RegoMel)

Melanoma Stage IV | Melanoma Stage III

Belgium
SC Liver Research Consortium, LLC
Bayer

Terminated

Optimization for Regorafenib in HCC (ReDos HCC)

Hepatocellular Carcinoma

United States
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens

Liver Metastasis Colon Cancer

China
Bayer

Terminated

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

Small Cell Lung Carcinoma

United States
University of Utah

Terminated

Regorafenib + Panitumumab for Colorectal Cancers

KRAS and NRAS Wild-type Colorectal Cancer

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Colorectal Cancer | Liver Metastasis
Centre Leon Berard

Recruiting

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA)

Osteosarcoma | Ewing Sarcoma | Chondrosarcoma | Leiomyosarcoma | Angiosarcoma | Bone Sarcoma | Undifferentiated Pleomorphic Sarcoma

France
Translational Research in Oncology
Bayer; Novartis

Withdrawn

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS)

Soft Tissue Sarcoma | Small Cell Lung Carcinoma | Colorectal Neoplasms | Anal Squamous Cell Carcinoma | Malignant Pleural Mesothelioma | Castrate Resistant Prostate Cancer | Gastroenteropancreatic Neuroendocrine Neoplasm | Neuroendocrine Carcinoma of Prostate
Incyte Corporation

Terminated

Study of Ruxolitinib in Colorectal Cancer Patients

CRC (Colorectal Cancer)

United States, France, United Kingdom, Spain, Israel, Australia, Germany, Korea, Democratic People's Republic of
Lei Liu

Not yet recruiting

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy...
Shanxi Province Cancer Hospital

Recruiting

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
Xuekui Liu

Recruiting

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma (NCCCNRHNSCC)

Head and Neck Squamous Cell Carcinoma | Locally Advanced Operable

China
Eureka Therapeutics Inc.

Recruiting

T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3)

Hepatocellular Carcinoma | Liver Neoplasm | Metastatic Liver Cancer | Liver Cancer, Adult

United States
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Unknown

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Bayer

Completed

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Metastatic Colorectal Cancer

Belgium, Italy, Spain, Canada, Japan, Czech Republic, United States, Australia, France, Hungary, China, Germany, Israel, Netherlands, Turkey, Portugal, Brazil, Switzerland, Argentina
Peking Union Medical College Hospital

Recruiting

Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

Cadonilimab and Lenvatinib

China
Sun Yat-sen University

Recruiting

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Clear Cell Renal Cell Carcinoma | Neoadjuvant Therapy | Cadonilimab

China
Peking University Cancer Hospital & Institute

Not yet recruiting

A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

Melanoma | Metastatic Melanoma | Mucosal Melanoma

China
Peking University Cancer Hospital & Institute

Recruiting

The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

Colorectal Liver Metastases

China
Health Science Center of Xi'an Jiaotong University

Recruiting

Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer (GCR-05)

Cervical Cancer

China
Hunan Cancer Hospital

Recruiting

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
West China Hospital

Recruiting

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Cholangiocarcinoma Non-resectable

China
Zhongnan Hospital
Akeso Biopharma Co., Ltd.

Recruiting

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Cervical Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC

Pancreatic Cancer

China
Sun Yat-sen University

Recruiting

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer (OPTICAL-2)

Colorectal Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Unresectable Hepatocellular Carcinoma | Oligometastatic Disease

China
Bayer

Completed

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Neoplasms

United States
Xijing Hospital

Not yet recruiting

An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC

Gastric Cancer

China
Sun Yat-sen University

Recruiting

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Hepatocellular Carcinoma | Pulmonary Metastases | Bevacizumab | Liver Cancer Stage IV | Cryoablation | Cadonilimab

China
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

China
Women's Hospital School Of Medicine Zhejiang University
Akeso

Not yet recruiting

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Cervical Cancer | Uterine Cervical Neoplasms | Cancer of Cervix | Uterine Cervical Cancer | Cervical Neoplasms | Cancer of the Uterine Cervix
Fudan University

Recruiting

Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study

Colorectal Liver Metastasis

China
Fundacion Clinic per a la Recerca Biomedica
Apices Soluciones S.L.

Active, not recruiting

Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) (GOING)

Hepatocellular Carcinoma

Spain
Fudan University

Recruiting

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS Mutation | Cadonilimab

China
Peking Union Medical College Hospital

Recruiting

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

Hepatocellular Carcinoma

China
Institut du Cancer de Montpellier - Val d'Aurelle

Recruiting

Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI)

Metastatic Colorectal Cancer (mCRC)

France
Shanghai Changzheng Hospital

Unknown

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

Colorectal Cancer | Immunotherapy

China
West China Hospital

Not yet recruiting

Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

Gastric Cancer
Akeso

Recruiting

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...
Akeso Pharmaceuticals, Inc.

Not yet recruiting

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Metastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
Asan Medical Center
Samsung Medical Center; Bundang CHA Hospital

Completed

Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma (RENOBATE)

Carcinoma, Hepatocellular | Hepatoma

Korea, Republic of
Istituto Oncologico Veneto IRCCS
Bayer S.p.A

Recruiting

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2)

Glioblastoma, IDH-wildtype | MGMT-Methylated Glioblastoma

Italy
Australasian Gastro-Intestinal Trials Group
European Organisation for Research and Treatment of Cancer - EORTC; Scandinavian...

Active, not recruiting

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)

Gastrointestinal Stromal Tumour

Singapore, Norway, Finland, Australia, Sweden, France, United Kingdom, Spain, Netherlands, Slovakia
China Medical University, China

Not yet recruiting

Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance

Gastric Adenocarcinoma
M.D. Anderson Cancer Center

Completed

Regorafenib and Cetuximab in Patients With Advanced Malignancy

Advanced Cancers

United States
Novartis Pharmaceuticals

Completed

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, Italy, Singapore, Canada, Israel, Korea, Republic of, Netherlands, Australia
Fudan University

Recruiting

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

Metastatic Colorectal Cancer

China
Peking University Third Hospital

Not yet recruiting

Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors (SCARCE)

Advanced Solid Tumor | Efficacy | Safety | Stereotactic Body Radiotherapy | Immune Checkpoint Inhibitor

China

Search clinical trials for: Cadonilimab regorafenib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations